Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5278348 | 0.98 | PTGDR2 (0.47) | PTGDR2SMN1; SMN2EPHX2TP53CASP1 | |
| SCHEMBL361128 | 0.97 | PTGDR2 (0.49) | PTGDR2SMN1; SMN2EPHX2TP53CASP1 | |
| SCHEMBL30764027 | 0.95 | PTGDR2 (0.43) | PTGDR2SMN1; SMN2EPHX2TP53CASP1 | |
| SCHEMBL9101971 | 0.95 | PTGDR2 (0.39) | PTGDR2SMN1; SMN2EPHX2MAPTALDH1A1 | |
| SCHEMBL21438419 | 0.91 | PTGDR2 (0.45) | PTGDR2SMN1; SMN2EPHX2LMNAMAPT | |
| SCHEMBL3387056 | 0.89 | PTGDR2 (0.36) | PTGDR2EPHX2MAPTALDH1A1NOS3 | |
| SCHEMBL9101617 | 0.89 | CHRNB2 (0.39) | PTGDR2SMN1; SMN2EPHX2TP53CASP1 | |
| SCHEMBL778056 | 0.88 | PTGDR2 (0.35) | PTGDR2EPHX2MAPTALDH1A1MEN1 | |
| SCHEMBL9099567 | 0.86 | SCN9A (0.38) | PTGDR2EPHX2MAPTALDH1A1ATM | |
| SCHEMBL16712213 | 0.85 | NOS3 (0.45) | PTGDR2SMN1; SMN2EPHX2TP53CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178119-A1 | Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| EP-1915371-A2 | BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007024651-A2 | BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178119-A1 | Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | PTGDR2 1769/4885SMN1; SMN2 765/4885EPHX2 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.